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INTRODUCTION 
 
According to the classical theory on neuro-regulation, sensory nerves transmit sensory stimuli 
and pain from various body parts (joints, skin, inter al organs) to the central nervous system. 
The other group of the peripheral nervous system is responsible for efferent reflexes triggered 
by incoming stimuli, i.e. motory or vegetative functions.  
From neuro-regulation’s theoretical point of view capsaicin-sensitive sensory nerves 
represent a special and interesting third group, the peripheral endings of which not only 
possess ’classical’ afferent functions (nociperception), but implement efferent functions as 
well. Directly, without reflex, certain neuropeptides are released from them, bringing forth 
forcible vessel dilation, plasma protein emission and inflammatory cell activation on the area 
of innervation. Epitomised, this phenomenon is called neurogenic inflammation. These 
inflammatory mediators are calcitonin gene-related p ptide (CGRP) which primarily causes 
vasodilatation, and the tachykinins, e.g.: SP and neurokinin A (NKA), that are responsible for 
plasma protein extravasation. These processes mediate loc l efferent functions of capsaicin-
sensitive afferents.  
Subsequent studies revealed that from these same activated sensory nerve endings, aside from 
the inflammatory neuropeptides listed above, somatost in (SOM) is also released, which has 
systemic anti-inflammatory and analgetic effects, once getting into the circulation.  
This is the third, systemic efferent function of sensory nerve endings, named sensocrin effect 
by Professor Szolcsányi, following the formula of smatostatin’s endocrin and paracrin effect.  
Capsaicin (Capsicum annuum és Capsicum frutescens) is the prickly substance of paprika, an 
alkaloid regarding its chemical structure: 8-methyl-N-vanillyl-6-nonenamide. Capsaicin 
effectuates its impacts via receptorial mechanisms. The capsaicin receptor expressing gene 
was identified in 1997, and the capsaicin receptor was named Vanilloid 1 receptor (VR1). 
Later the international nomenclature based on the structure of receptors altered this 
denomination, the ligand-dependent cation channel was classified into the Transient Receptor 
Potential (TRP) family, and as number 1 member of the vanilloid family, it was then renamed 
Transient Receptor Potential Vanilloid 1 (TRPV1).  
TRPV1 is a cation channel with polymodal sensor functio , which can be activated by several 
physical or chemical stimuli – e.g.: painful temperatu e, above 43 ºC and proton concentration 
below pH 6 – both intra- and extracellularly. When the receptor is activated, Na+ nd Ca2+ 
ions stream in, followed by outflow of K+ ions from the cell. Inflow of Na+ ions is mainly 
responsible for creating action potential, as a consequence of which nociception, sensation of 
pain evolves. Influx of Ca2+ causes release of neuropeptides from nerve endings.  
As a result of enduring or repeated activation the high cation concentration accumulated in the 
cell causes swelling of cytoplasm and mitochondria, and as a long-term consequence energy 
circulation of the cells decrease, the nerve ending becomes nonfunctional.  
This process gives the molecular basis of desensibilization by pre-treating with high doses of 
capsaicin. A new perspective came regarding the analysis of receptor TRPV1 when in 2000 
two separate research groups generated TRPV1 receptor knockout mice. With the help of 
these mice, the relevance and functioning of TRPV1 ion channel can be studied selectively in 
in vivo models.  
Systemic anti-inflammatory somatostatin released during the TRPV1 receptor activation 
could be a promising anti-inflammatory and analgetic drug, however the therapeutic use of 
native somatostatin is inhibited by its wide spectrum and extremely short (less than 3 minutes) 
plasma elimination half-life. Stabile, selective sst4/sst1 agonists can however provide a new 
therapeutic opportunity in treating inflammation and pain.  
The great advantage of these compounds is that they do not possess the endocrine effects 
mediated by somatostatin’s sst2, sst3 és sst5 receptors. The stabile cyclic heptapeptide 
generated by the MTA Peptidobiochemical Research Group, TT-232 (D-Phe-Cys-Tyr-D-Trp-
Lys-Cys-Thr-NH2), seems a promising drug candidate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS OF THE STUDY 
 
Skin and joints are especially richly innervated by capsaicin-sensitive sensory nerve fibers, 
which possess important modulating functions in neurogen processes and processes 
accompanied by pain. Hence in our experiments we performed the complex study of 
peptiderg sensory neuron endings, the TRPV ion channels localized on them and the sensory 
neuropeptides released from them, on scleroderma and arthritis models through biochemical, 
immunological and morphological methods.  
 
1. In the first section of the study using TRPV1 receptor and CGRP knockout mice, we 
examined the relevance of TRPV1 receptor and the rol of the vasoactive sensory 
neuropeptide, CGRP released with its activation, in the pathomechanism of fibrotic and 
inflammatory skin mutation induced by bleomycin. 
 
2. a) Second phase of the examinations was aimed at discovering the role of capsaicin-
sensitive afferents and the somatostatin of sensory origin in chronic arthritis and subsequent 
hyperalgesia in rheumatoid arthritis rat model.  
b) In addition we also examined the effects of synthetic heptapeptide sst4 receptor antagonist 
TT-232 in this same model.  
c) Furthermore we also aimed at examining the activtion/sensitization mechanisms of 
TRPV1 receptors localized on the sensory nerve fibers, in chronic arthritis knockout mice 
with the help of enzyme inhibitors.  
 
 
 
 
 
 
 
 
 
 
CHAPTER I   
 
THE ROLE OF THE TRPV1 RECEPTOR AND CGRP IN BLEOMYCIN INDUCED 
SCLERODERMA MOUSE MODEL USING RECEPTOR KNOCKOUT MICE.  
 
1. Literary background to our experiments: 
Scleroderma is an autoimmune disease of unknown origin, most frequently it appears in the 
forties, and is ten times more common in women.  
The characteristic features of the disease can affect only the skin and the subcutaneous tissues, 
in this case we are facing local scleroderma, or itcan affect various internal organs as well, in 
which case it is called systemic. Systemic can be divided into diffuse and limited forms.  
The increased collagen biosynthesis of fibroblasts ha  already been proved to contribute to the 
development of the condition, however, it is still unknown, what induces the cells to figuratively 
’strangle’ the tissues with collagen. Two main hypotheses are known regarding the etiology. 
According to the immunological hypothesis, fibrosis i  a secondary anomaly, which is due to the 
abnormal activation of the immune system. It has been presumed, that the T-cells responding to 
the unknown antigen accumulate in the skin and effectuate the fibrotic alterations through the 
cytokines produced by them. By the vascular hypothesis, recurrent lesions of the micro vascular 
endothelium are the primary etiology factors.  
The areas affected by the disease are the skin, the muscular-skeletal system, the gastrointestinal 
tract, the lungs, the kidneys and the heart. Currently there is no medicine that can cure 
scleroderma, treatment is primarily symptomatic.  
Scleroderma, similarly to other autoimmune diseases, most frequently commences with 
Raynaud-symptom, which means the symmetrical pallor nd cyanosis of the acral areas of the 
body due to cold or emotional stress factors. It isalready a known fact, that in the skin samples 
of scleroderma patients showing signs of Raynaud manifestation, the number of CGRP 
immunoreactive neurons is significantly reduced compared to healthy control patients.  
Several animal models have been designed for the exp rimental study of scleroderma but 
hitherto there is no model that carries all the features of clinical scleroderma.  
We used a belomycin induced local scleroderma model designed by Yamamoto for our 
experiments. In this model alteration typical of scleroderma developed as a result of continuous 
local bleomycin treatment.  
Bleomycin is an antitumor antibiotic produced by Str. verticillus. It works well on planocellular 
carcinomas of different localization. It is used esp cially in the treatment of scrotum cancer, 
head-neck tumors, lung carcinoma and esophagus carcinoma. Fibrosis of the lungs is a well-
known side-effect.  
 
2. Materials and methods: 
For 30 days 0,1 ml 100 µg/ml concentration of bleomycin was injected under th  dorsal skin 
of mice, the control group got the solvent of bleomycin, phosphate buffer (PBS) in the same 
volume, under the dorsal skin.  The animals were then divided into four-four groups.  
During examination of the role of TRPV1 receptor bleomycin treated TRPV1+/+ (wild), 
bleomycin treated TRPV1-/- (KO), PBS treated TRPV1+/+ (wild) and PBS treated TRPV1-/- 
(KO) groups were created, number of individuals in each group was 10-12 animals.  
In the experiments aimed at the clarification of the role of CGRP receptor, bleomycin treated 
CGRP+/+ (wild), bleomycin treated CGRP-/- (KO), PBS treated CGRP+/+ (wild), PBS treated 
CGRP-/- (KO) groups were formed, with 8-10 individuals in each.  
On the day following the administration of the last bleomycin injection, the mice were 
narcotized to sleep, and a section 6 mm in diameter was cut out from their nape. Samples 
were submitted to the following examinations:  
 
Histological examinations:  
After embedding in paraffin, the samples were stained with haematoxylin eosin and 
picrosyrius which paints collagen intent red. The dgree of the evolving sclerosis was 
determined via semiquantitative histological scoring. In every sample, thickness of skin, 
intensity of the inflammation, structured form of collagen bundles were scored form 0-4, thus 
the final score could be in the range 0-12.  
 
Measuring thickness of skin:  
Thickness of cut-out skin was determined through 40x magnification, expressing the distance 
between dermo-epidermal junction and dermo-subcutan j nction in micrometers.  
 
Determining the number of myofibroblasts:  
Determining the number of myofibroblasts proliferating in scleroderma-affected skin was 
done by immunohistochemical staining of α-smooth muscle actin (α-SMA) which is typical in 
myofibroblasts. 
 
Determining hydroxiproline content biochemically:  
Hydroxiproline is almost exclusively found in collagen of connective tissue and in elastin, 
therefore it is widely used as means of detecting the presence and amount of collagen. 
Hydroxiprolin content of the samples was determined using spectrofotometric methods, by a 
previously prepared standard curve. Values were expressed in microgram hydroxiproline 
content.  
 
Quantitative analysis of the level of type-I collagen α1-chain mRNA, by RT-PCR method:  
Total RNA content of the samples were isolated, the examined specific mRNA levels were 
amplified and determined by using LightCycler quantit tive PCR system.  
 
Statistical methods:      
Results were expressed in mean ± SEM, applied to each group. For analysing the 
experimental methods, non-parametric Mann Whitney U-probe was used. A p-value ander 
0.05 was considered significant difference among the analysed groups.  
 
3. Results: 
3.1. Examining bleomycin induced model in TRPV1+/+ (wild type) mice: 
The cumulative sclerosis score was 58% higher (6.33±0.19 and 4.00±0.31), skin thickness 
was increased by 42% (393.05±15.41 µm and 278.62±11.38 µm), and number of α-SMA-
positive cells was extended by 75% (16.33±3.31 and 9.3±1.34 in each focus) in bleomycin 
treated TRPV1+/+ group, compared to the PBS treated TRPV1+/+ group. 
Similarly to the histological alterations, the conte t of spectrofotometrically determined 
collagen specific amino acid, hydroxiproline was also significantly, by 47.5% higher 
(118.5±6.7 and 80.3±10.2 µg/skin sample) in the bleomycin treated group compared to the 
PBS-treated group of mice.  
Treating with PBS in itself did not result in significant histological alterations as compared to 
skin samples of the untreated TRPV1+/+ mice. There was no detectable difference between 
untreated TRPV1+/+ and TRPV1-/- mice’s histological skin structure.  
3.2. Examining the role of TRPV1 receptor in skin sclerosis: 
As a result of bleomycin treatment histological altera ions of TRPV1-/- (KO) animals were 
more expressed, the summarized sclerosis score was significantly higher (7.46±0.20 and 
6.33±0.19) compared to the bleomycin treated  TRPV1+/+ (wild) group. 
Value for thickness of the skin was also significantly higher (464.86±10.15 µm and 
393.05±15.41 µm) and number of α-SMA-positive cells was also highly increased 
(24.03±3.07 and 16.33±3.31 in each focus) in bleomycin treated TRPV1-/- group compared to 
the also bleomycin treated TRPV1+/+ group. 
In accordance with the histological changes, the hydroxiproline content of the samples was 
also 57% higher (186.605±8.4 and 118.5±6.7 µg/skin ample) in bleomycin treated TRPV1-/-  
group compared to TRPV1+/+ group. There was no sognificant difference neither with 
histological methods or biochemical measuring of hydroxiproline content between PBS 
treates TRPV1-/- and PBS treated TRPV1+/+ samples. 
 
3.3. Analysing the expression of type-I collagen α1 chain mRNA in sclerotic skin:  
Examining the levels of type-I collagen α1 chain mRNA, compared to the wild, PBS treated 
group, no significant difference can be detected in mRNA expression of the groups. 
Significant difference could not be found in levels of type-I collagen α1 chain mRNA by the 
end of the 4-week treatment, hence the degree of type-I collagen α1 chain mRNA in animals 
killed in an earlier phase of the experiment (after 2 weeks) was also examined, but significant 
discrepancy could not be detected resulting from bleomycin treatment. 
Based on the results, it can be concluded that bleomycin treatment does not affect expression 
of type-I collagen α1 chain mRNA.  
 
 
3.4. Examinig the role of CGRP receptor in sclerodema model:  
Histological examinations showed that the complex sclerosis score was 42% higher in 
bleomycin treated CGRP+/+ group (4.25±0.38 and 2.98±0.51), 52% higher skin thickness 
values (434.49±16.41 µm and 285.85±17.36 µm) and 62% more α-SMA-positive cells 
(15.83±3.6 and 9.75±0.88 in each focus) compared to the respective PBS treated groups. The 
amount of hydroxiproline increased by 47% (137.6±14.58 and 93.4±10.65 µg/skin sample) as 
a result of bleomycin treatment compared to control CGRP+/+ PBS treatment.  
Absence of CGRP receptor resulted in increased sclerotic changes with bleomycin tretment, 
the complex sclerotic score was significantly increas d (6.21±0.58 and 4.25±0.47) in 
bleomycin treated CGRP-/- (KO) group compared to bleomycin treated CGRP+/+ (wild) group. 
Skin thickness showed an increase of 29% (557.23±18. 8 µm and 434.49±16.41 µm) in 
bleomycin treated CGRP-/- group as compared with the similarly treated CGRP+/+ group. The 
number of α-SMA-positive cells also increased significantly (27.83±4.58 and15.83±3.60 in 
each focus) in bleomycin treated CGRP-/- group compared to the also bleomycin treated 
CGRP+/+ group.  
In accordance with the histological changes, hydroxipr line content of the samples was also 
significantly higher (179.30±18.90 and 137.60±14.58 µg/skin sample) in bleomycin treated 
CGRP-/- group compared to CGRP+/+ group.  
Surprisingly, on the skin of PBS treated CGRP-/- animals increased sclerotic changes were 
also perceivable as an elevated complex sclerosis score (3.96±0.49 and 2.98±0.51), higher 
skin thickness values (386.25±10.26 µm and 285.85±17.36 µm), increased α-SMA-positive 
cell count (15.04±2.39 and 9.75±0.88 in each focus) and increased hydroxiproline content 
(126.56±13.10 and 93.4±10.65 µg/skin sample) could be observed compared to the PBS 
treated CGRP+/+ group. The sclerotic changes developing in PBS treated CGRP-/- group were 
similar in extent to those in the bleomycin treated CGRP+/+ group, therefore we examined the 
non-treated CGRP knockout and wild mice skin samples as well and we discovered that there 
is no significant difference neither in histological structure, nor in hydroxiproline content 
between non-treated animals.  
 
4. Discussion, conclusion: 
In these series of experiments we focused our study on the role of TRPV1 receptor and CGRP 
in chronic fibrotic-sclerotic circumstances. The 30-day bleomycin treatment in the TRPV1+/+  
mice created from C57BL/6 tribe, resulted in approximately 150% skin thickening, 
remarkable, histological estimated skin sclerosis, 75% more increased α-SMA-positive cell 
count, and 148,5% increased hydroxiproline content as compared to the PBS treated 
TRPV1+/+ group used as control. These results were in accordance with previous results in 
literature regarding the C57BL/6 tribe. In contrast with previous findings the increase in the 
level of type-I collagen α1 chain mRNA could not be detected via quantitative PCR. It is not 
accurately clarified what might be the background of this observation, however the elevated 
amount of collagen protein beside normal mRNA levels can be deduced to a number of 
reasons, e.g.: a decrease in the degradation of collagen, increased translation, increased 
collagen maturing processes.   
Absence of TRPV1 receptor in the examined bleomycin induces scleroderma model definitely 
aggravates sclerotic skin alterations, supported by histological and biochemical examination 
results. In bleomycin treated TRPV1-/- (KO) animals there was a significantly higher complex 
sclerotic score, higher skin thickness values, an elevated number of α-SMA-positive cells and 
az increased hydroxiproline content was measured as compared with the similarly bleomycin 
treated TRPV1+/+ (wild) animals. There is no detectable difference between the skin structure 
of non-treated knokcout and wild animals, therefore the absence of TRPV1 receptor in itself 
does not cause fibrotic-sclerotic changes. For sclerotic alterations to develop profibrotic 
factors, like bleomycin are needed to be present. 
Based on our results it can be declared, that presenc  of the TRPV1 receptor has a protective 
effect against sclerotic alterations induced by profib tic agents. Supposedly the inflammatory 
mediators from inflammatory processes induced by bleomycin activate and sensibilize the 
TRPV1 receptor, which leads to the emission of sensory neuropeptides, which have protective 
effects against phatological changes, in the models studied in our research. 
From the sensory neuropeptides released during activation of TRPV1 receptor data can only 
be found on CGRP in the literature, as a potentially protective factor in the pathomechanism 
of scleroderma and Raynaud’s phenomenon. Based on these observations we used CGRP 
knockout mice to clarify the role of CGRP in sclerotic processes in the in vivo bleomycin 
induced scleroderma model used in our study. In CGRP+/+ group, created from C57BL/6 tribe, 
bleomycin treatment resulted in relevant morphological, biochemical, histological and 
immunohistochemical (α-SMA) changes. In the absence of CGRP, bleomycin treatment 
definitely caused increased sclerosis, regarding skin thickness, histological score, 
hydroxiproline and α-SMA. Our experiments provide the first in vivo proof of sclerotic 
alterations developing in the absence of CGRP. Presumably the vasospasm and resulting 
ischemia is in the background, caused by the lack of CGRP’s vasodilatative effects. 
Concluding the results of our study, we can state, hat presence of TRPV1 receptor and CGRP 
proves to have a definite protective role against the pathomechanism of scleroderma. CGRP 
agonists can have future therapeutic potential in the treatment of scleroderma, but naturally, 
the possible side-effects will have to be taken into consideration as well.  
 
 
 
 
 
CHAPTER II.  
 
THE ROLE OF CAPSAICIN SENSITIVE NEURON ENDINGS AND TRPV1 RECEPTOR 
IN ADJUVANT-INDUCED CHRONIC ARTHRITIS MODEL 
 
1. Literary background to our experiments: 
Rheumatoid arthritis primarily affects young, middle-aged women, in Hungary some 70-80 
thousand patients can be taken into account. This disease is a chronic, progressive multi-joint 
inflammation of autoimmune origin, which causes pain, a disabled state, disability and a 
serious deterioration in the quality of life via destruction of joints and deformities. The joint 
case and the synovium are richly innervated with capsaicin-sensitive fibers. These nerve 
endings mediate strain and pain, furthermore numerous literary data justifies that the 
neurogen inflammation mediated by them plays an important role in the development of 
chronic arthritis. In the synovial fluid of patients suffering from arthritis, elevated levels of 
inflammatory sensory neuropeptides were shown. There is literary data however, proving 
that other neuropeptides (opiois peptides, galanin, somatostatin) also released from activated 
sensory nerve endings inhibit the development of chronic arthritis in experimental 
circumstances. Concerning arthritis, there is literary evidence for the pathophysiological 
relevance of both inflammatory and anti-inflammatory neuropeptides released from 
capsaicin-sensitive neuron endings. 
Current therapy of chronic arthritis is primarily only eases the symptoms. At first non-steroid 
anti-inflammatory drugs/painkillers are recommended, while in an advanced state of the 
disease steroids and later immunosuppressive base-therapy drugs (methotrexate, leflunomid) 
can be administered. The causal therapy of this group of diseases is thus far from being 
solved, and there is no single drug on the market which could effectively block the 
neurogenic component of inflammation.  
 
2. Materials and methods: 
Chronic arthritis was triggered by complete Freund adjuvant (CFA, killed Mycobacterium’s 
suspension in paraffin oil, 1mg/ml), in rats, 100 microliters, in mice 50 microliters 
subcutaneously into the left soles and to the tail s em. Inflammatory reaction develops in the 
tibio-tarsal joints, accompanied by systemic inflammatory symptoms (elevation in body 
temperature, weight loss, fatigue) which are more pronounced on the side of the injection, as a 
result of CFA, but can nonetheless be observed on the opposite side as well. 
A. Experiments with rats: 
In our experiments, 4 animal groups were formed, an in each of them, arthritis was induced 
as described above.  
To examine the role of capsaicin-sensitive afferent s sory fibers, one group of rats were pre-
treated by RTX, a TRPV1 antagonist, which causes damage to these sensory nerve endings. 
During the pre-treatment, on three consecutive days 30, 70 ans 100 µg/kg RTX was given to 
the animals subcutaneously under the skin of the neck. Arthritis was induced 7 days later. In 
order to verify the success of RTX desensibilisation, before starting the experiment, wiping 
test was performed by dropping capsaicin into the ey s (50 µl of 0,1% capsaicin), the 
avoiding wiping reaction was absent in all pre-treated animals. 
For the study on the role of somatostatin – which is released when capsaicin sensitive nerve 
endings are activated – another group of the rats w treated with sst receptor antagonist 
cyclo-somatostatin (C-SOM) daily, for 21 days (20 µg/kg i.p.). 
In the next series of experiments, the rats were treated with synthetic heptapeptide sst4/sst1 
agonist TT-232 during the entire procedure of the experiment (2x50-400 µg/kg/nap i.p.), in 
the control group, solvent was used.  
 
B. Experiments with mice: 
To study the possible activation of TRPV1 receptor in chronic arthritis’ conditions, a group 
of both TRPV1 receptor knockout and wild-type animals (n=8-12/group) were treated by one 
of the following materials from the beginning of the adjuvant therapy, every day, during the 
entire experimental procedure. The tested compounds were chosen to identify the possible 
mediators playing a role in the activation of the TRPV1 receptor.  
To study the role of lipooxygenase enzyme products in he activation of TRPV1, one group 
of animals was treated with nor-dihydro-guaretic acid (NDGA), a non-selective 
lipoogygenase-inhibitor, in a dose of 25 mg/kg/day intraperitoneally (ip.). The second group 
of animals was treated with  bradykinin B1 receptor antagonist desArgHOE-140 to reveal the 
possible sensitizing effect of bradykinin, while the third group was treated with  bradykinin 
B2 receptor antagonist HOE-140 (in both cases 250 µg/kg/day ip.). 
Mice of the fourth group got indomethacin (1mg/kg ip.), a non-selective cyclooxygenase 
enzyme inhibitor, to study the possible TRPV1 receptor activating and sensitizing effect of 
cyclooxygenase enzyme products.  
As control group for the individual group’s studies, there was a group treated with i.p. saline.  
Test methods:  
 
Paw edema measurement:  
Volumes of the legs were measured with Ugo Basile 7140 plethysmometer, which is a device 
operating on the principle of communicating vessels. The volumes were read off from the 
digital display in cm3-s on the day 2, 5, 8, 12, 15, 18, 21 of the experim nt, the measured data 
were then compared with data from the baselin and expressed as a percentage of the edema.  
 
Measurement of the mechanonociceptive treshold: 
Ugo Basil dynamic plantar esthesiomether was used to e ermine the mechanociceptive 
threshold of the feet. This is the digitalized version of classical von Frey method.  
During the experiment, the middle region of the animals’ feet was stimulated with a stainless 
steel flat mandrel, with pre-set dynamic parameters. The threshold value at which the animal 
lifts its feet can be read from the digital display expressed in grams. 
Every result was calculated from the average of three consecutive measurements, the 
mechanical threshold was expressed compared with the initial values, in percentages.  
 
 
Preparation and evaluation of histological sections:  
Tibiotarsal joint of narcotized animals, killed by cervical dislocation was cut out, was fixated 
in formalin and then it was decalcinated. When the joints softened enough, samples were 
embedded into paraffin, then cut into 5-7 µm slices and then stained with hematoxylin-eosin. 
The inflammatory changes were then evaluated by an independent, experienced pathologist 
colleague. Semi quantitative scoring was based on the scale of thickening of the synovial 
connective tissue, leukocyte infiltration, and on the rate cartilage and bone damage 
separately. Each of the four parameters were scored on a scale from 0 to 3, the points were 
added, thus for every sample, and thus for every group a complex arthritis score was obtained 
with a value ranging from 0 to 12.  
 
Determination of plasma somatostatin concentration:  
At the end of the experiment, 4 ml blood samples were taken from each rat via punctuating 
the heart in deep anesthesia. The blood samples were transferred into iced tubes containing 
EDTA and aprotonin. After centrifugation the plasma peptide content was extracted with 
absolute alkohol, the supernatant was dried under a stre m of nitrogen, and was then resolved 
in RIA-buffer. Somatostatin-like immunoreactivity of the plasma  was determined by RIA.  
 
Statistical analysis: 
To statistically analyse of paw edema, allodynia/hyperalgesia after two-way ANOVA, 
Bonferroni correction t-test was used. For analyzing the complex arthritis score and plasma 
peptide concentrations, the non-parametric Mann-Whitney U test was applied. A value of p 
under 0.05 was regarded significant difference in all cases in the studied groups.  
 
3. Results: 
3.1. The role of capsaicin sensitive fibers and the somatostatin released from them in a rat 
model of chronic arthritis:  
In control non pre-treated animals, the foot treated with CFA gradually swelled, and on the 
eights day it reached 60% of the maximum, the volume increased from 0.73±0.02 cm3 to 
1.18±0.13 cm3. On the contra lateral foot, only a smaller edema was observed, of 16-18%.  
After inactivation of capsaicin-sensitive afferent fibers with RTX pre-treatment, the edema of 
the entire 21-day experimental period was larger, the daily applied C-SOM injection, which 
inhibits the effects of somatostatin on all five sst receptors, increased the foot swelling to the 
similar extent as the RTX pre-treatment.  
In the control animals the CFA treatment caused the mechanociceptive threshold to decrease 
significantly, on the leg treated with CFA, it decrased by 25-30%, while on the contra lateral 
leg, by only 5-7%. The pre-treatment with RTX and C-SOM treatment significantly 
increased allodynia on both legs during the entire 21-day experimental period.  
The histological sections show, that the CFA-treated left joint of the rats is damaged by the 
continually growing synovial pannus. The synovial cvity is expanded, synovial connective 
tissue is densely infiltrated with mononuclear cells, the cartilage is heavily eroded, and 
massive bone loss can be observed. Minor inflammatory changes can be seen in the contra 
lateral joints, cartilage and bone damage rarely occurs, mononuclear cell infiltration is 
significantly less severe, in some parts, the synovial tissue is thickened.  
In the tibiotarsal joint of rats pre-treated with RTX and treated with C-SOM, as a result of 
CFA a much more pronounced synovial hyperplasia, more prominent thickening and 
mononuclear cell infiltration, and furthermore much greater cartilage damage and advanced 
bone loss can be seen. In both groups, the contra la era  joints show more intense 
inflammatory lesions. The arthritis score results have also confirmed that both RTX pre-
treatment, and C-SOM treatment significantly aggravate the arthritis.  
SOM-like immunoreactivity of the plasma increased steadily following the CFA-injection, 
and by the 21st day, it reached four times the maximum value. Pre-treatment with RTX 
significantly reduced SOM release during the inflammation, the basal level did not change.  
 
3.2. Effect of TT-232-treatment on CFA-induced chronic arthritis:  
TT-232 decreased the CFA-induced leg-edema in a dose- ependent way, the highest dose 
causing 50% inhibition on the CFA-treated leg. Highest doses of TT-232 prevented the 30% 
mechanical allodynia measured in the control group, and moreover, surprisingly it has also 
resulted in a rise in the threshold value. Edema and hyperalgesia completely ceased on the 
contra lateral side. Tibiotarsal joint of the rats treated with the highest doses, showed signs of 
milder inflammatory reactions. Synovial swelling, lymphocyte accumulation and destruction 
of cartilage was reduced, bone damage did not develop. This is also confirmed by the 
complex arthritis score, which was significantly smaller on both legs as compared with the 
control group treated with solvent. During the entire experimental period the TT-232 injected 
intraperitoneally two times per day inhibited the CFA-induced elevation of somatostatin-like 
immunoreactivity of the plasma in a dose-dependent manner. The highest dose reduced the 
somatostatin concentration to the basal value. 
 
3.3. CFA-induced paw edema, mechanical hyperalgesia and histological changes in 
TRPV1+/+ and TRPV1-/- mice: 
In wild mice, paw edema on the treated side increased teadily, reaching the maximal 
swelling on the 16th day (130% swelling compared to the baseline value), on the contra lateral 
leg, smaller edema developed (30%). In case of TRPV1-/- mice significantly smaller swelling 
developed on both sides from the first day of measurements, throughout the entire 
experimental period (a maximum of 80% swelling on the reated and 15% on the contra 
lateral leg).  
Mechanociceptive threshold in the CFA-treated leg of wild-type animals decreased by 45-
50%, while on the contra lateral side, only 10-15% hyperalgesia was developed. In contrast, 
threshold value of TRPV1-/- mice showed only 30-35% decrease on the treated leg, while no 
hyperalgesia developed on the contra lateral side.  
Compared to intact joint structures, in histological sections of CFA-treated tibiotarsal joints of 
wild mice, tissue destruction could be found similar to those observed on rats. There was a 
significantly smaller degree of cartilage destruction without bone damage inTRPV1-/-  mice, 
and thickening of the synovial tissue and mononuclear cell infiltration was also somewhat 
milder, consequently the complex arthritis score was also significantly lower (7.8 ± 1.1 vs. 4.6 
± 1.2). 
3.4.  
3.4. Effect of desArgHOE-140, HOE-140, NDGA and indomethacin on CFA-induced paw 
edema, hyperalgesia and histological alterations in wild-type and TRPV1-/-mice: 
The bradykinin B1 receptor antagonist desArgHOE-140 did not induce any significant 
alterations on either CFA-evoked edema or mechanical hyperalgesia and did not remarkably 
altered the composite arthritis score. In contrast, the bradykinin B2 receptor antagonist HOE-
140 exerted a 30-40% inhibition on paw swelling and hyperalgesia throughout the total 
duration of the study, the histological score was also reduced by 55%. The inhibitory action 
of the non-selective lipoxygenase inhibitor NDGA was 40-50%, while that of the 
cyclooxygenase inhibitor was 60-80% on the inflammatory mechanical hyperalgesia. NDGA 
diminished edema formation by 25-30%, indomethacin by 40-55%, and the arthritis score 
was also decreased by 40% and 65% in response to treatments with these agents, 
respectively.  
In the TRPV1-/- group, however, NDGA and HOE-140 did not influence any of the 
inflammatory parameters. Treatment with the B1 receptor antagonist desArgHOE-140 was 
not investigated in the knockout group, since it did not have any statistically significant 
action in the wild-types. Indomethacin decreased hyperalgesia by 50-60%-kal and edema by 
20-30%. In contrast to what was seen in the wild-type animals, indometacin did not decrease 
edema in TRPV1-/- mice in the early period of the experiment, the first significant action as 
observed 11 days after CFA injection. Furthermore, both the antihyperalgesic and the anti-
edema effects were smaller than that found in the TRPV1+/+ group. No effects of NDGA and 
HOE-140 was seen on the inflammatory histopathological parameters in TRPV1-/- mice 
compared to the solvent-treated control group, while indomethacin treatment resulted in 
40%-decrease of the composite inflammation score. 
 
4. Discussion and conclusions: 
We provided direct chemical evidence in a rat model of chronic arthritis that stimulation of 
the peripheral terminals of capsaicin-sensitive prima y sensory nerves results in a 4-fold 
increase of somatostatin level in the systemic circulation. This was markedly inhibited after 
the inactivation of the capsaicin-sensitive afferents by RTX pretreatment. In chronic arthritis a 
variety of receptors and ion channels on these sensory nerves of the joints are presumably 
activated. As a result of all all these, SOM is released, gets into the systemic circulation and 
exerts anti-inflammatory and anti-hyperalgesic actions. These are concluded according to the 
fact that the non-selective sst receptor antagonist C-SOM-treatment made the inflammatory 
parameters more severe similarly to RTX-pretreatmen. These results provide evidence for the 
protective role of capsaicin-sensitive fibres in chronic arthritis and endogenous counter-
regulatory mechanism mediated by somatostatin of sensory neural origin. Based on all these 
data, SOM might have interesting for therapeutic purposes, but it cannot be an ideal drug 
candidate due to its 3-min plasma elimination half-life and its broad range of other, 
particularly endocrine, actions through the activation at all sst receptors. Stable, synthetic 
somatostatin agonists, particularly non-peptide ligands, which potently decrease inflammatory 
and nociceptive processes without influencing hormone secretion, might open promising 
perspectives for the development of a completely novel group of safe anti-inflammatory and 
analgesic drugs.   
On the basis of these results, in the next series of xperiments we investigated the effects of 
the selective sst1/sst4 receptor agonist TT-232, which does not exert any endocrine actions, in 
the same rat model of chronic arthritis. Chronic trea ment with TT-232 (2x400 µg/kg i.p.) 
reduced paw edema by about 50% and turned hyperalgesi  into hypoalgesia.  Furthermore, 
the inflammatory histopathological parameters were also remarkably attenuated, only a small 
pannus formation, moderate inflammatory cell infiltration and minimal cartilage destruction 
were observed, but no signs of bone destruction could be detected. 
In the second experimental setup, the adjuvat-induce  hronic arthritis model originally 
developed in Lewis rats were adopted and modified for C57Bl/6 mice. We proved that this is 
a reliable model also in this strain, since a 130% edema and 50% mechanical hyperalgesia 
developed on the injection side.  
Studies with TRPV1-/- mice in this CFA-induced arthritis model clearly revealed that the lack 
of this ion channel localized on the capsaicin-sensitive significantly decreased all 
inflammatory parameters on both side. Our results are the first evidence that the TRPV1 
receptor plays an important regulatory role in chronic arthritis and consequent mechanical 
hyperalgesia. It can be assumed that pro-inflammatory sensory neuropeptides released in 
response to its activation aggravate the intensity of the inflammatory response in the joints 
and also contribute to the decrease of the mechanonociceptive threshold.   
As a next step we aimed at identifying the inflammatory mediators which are responsible for 
the activation of the TRPV1 receptor. After an extensive literature search, the roles of  
bradykinin, lipoxygenase and cyclooxygenase products were investigated. It is important to 
emphasize that we did not want to analyze which mediator is the most important in the 
development of the inflammatory reaction, but the difference observed in the effects of these 
agents in the wildtype and TRPV1-/- groups. The lipoxigenase enzyme inhibitor nor-dihyro-
guaretic acid (NDGA) significantly reduced the mechanonociceptive threshold in the treated 
wild-type animals from the second experimental day.  On the contrary, the antinociceptive 
and anti-inflammatory effects were completely missing in the TRPV1 KO animals. The daily 
treatment with bradykinin B2 antagonist HOE-140 reduced the development of edema 
formation and mechanical hyperalgesia in the wild-type group but these effects were not 
shown in KO mice. These observations support previously published in vitro data, that 
bradykinin released during inflammatory processes acting on bradykinin B2 receptors 
sensitizes TRPV1 receptors on the peripheral sensory ne ve endings.  The bradykinin B1 
receptor antagonist desArgHOE-140 treatment did not i fluence significantly inflammatory 
changes in the wild-type group. On the basis of these r sults we conclude that bradykinin B1 
receptors do not play role in the chronic joint inflammation model in mice.  The 
cyclooxygenase enzyme inhibitor indomethacin signifcantly reduced (in the highest degree 
among the examined compounds) the arthritis and mechani al hyperalgesia in both treated 
animal groups compared to the solvent treated animals but the degree of inhibition was 
remarkably smaller in the TRPV1 receptor gene-deficient  mice especially in the inicial phase 
of the chronic inflammation. According to the present xperimental data, it is concluded that  
prostaglandins released from the inflamed tissue contribute to the enhancement of edema by  
activation/sensitization of TRPV1 receptors. 
The lack of TRPV1 receptors on the capsaicin-sensitive sensory nerve endings, in contrast to 
the total inactivation of the nerve ending-does not i crease but notably inhibited the signs of 
the arthtritis and hyperalgesia. This apparent contradiction can be explained with the facts that 
proinflammatory  and anti-inflammatory neuropeptides are released by activation of different 
receptors-/ion channels. Activation of TRPV1 receptors mainly causes the release of 
proinflammatory neuropeptides. The genetic lack of TRPV1 receptors significantly inhibits 
the inflammation and hyperalgesia in mice. We presume other mechanisms in the release of 
somatostatin. Previous data have been published that sensory neuropeptides only partly co-
localize in the capsaicin-sensitive afferents (Hökfelt és mtsai., 1976), it can be supposed that 
somatostatin-containing nerve endings express dominantly not TRPV1 but even more  
TRPA1, bradykinin- and purinergic, etc. receptors. 
We have indentified some potential target molecules, the TRPV1 ion channel and 
somatostatin sst4/sst1 receptors. Selective TRPV1 antagonists, or sst4/sst1 agonists can be new 
perspectives in the pharmacotherapy of the chronic arthritis. 
 
 
SUMMARY OF ORIGINAL FINDINGS OF THE THESIS 
 
1. On the basis of our experimental data we can conclude that TRPV1 receptors and CGRP 
have protective role in the pathomechanism of sclerod rma. CGRP receptor agonists can be 
new perspectives in e pharmacotherapy of scleroderma in the future but we have to consider 
the potential unwanted effects. 
 
2. We have presented evidence that somatostatin released from the capsaicin-sensitive sensory 
nerve endings plays protective role in the development of arthritis. 
 
3. A stable synthetic heptapeptide sst4/sst1 receptor agonist TT-232 efficiently inhibits the 
chronic joint inflammation (edema and histopathological changes) and inflammatory 
mechanical allodynia as well; therefore it can open promising perspectives in the drug 
development. 
  
4. It has been proven that TRPV1 ion channels expressed on the capsaicin-sensitive afferents 
can be sensitized by bradykinin, prostaglandins and lipoxigenase products. Selective TRPV1 
receptor activation, in contrast to the stimulation f the whole sensory nerve endings, 
increases the inflammation and allodynia. On the basis of these observations, the usage of 
selective TRPV1 receptor antagonists could also mean n w therapeutic tools in the treatment 
of arthtritis 
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